Minomic Archives - We are Minomic

Minomic’s video from MedTech Cybersecurity Innovation Summit

by Minomic | May 7, 2021

The 2021 Macquarie Park MedTech/Cybersecurity Innovation Summit, which was held on 29 April, brought together industry, Government and academia in the local MedTech sector. This event formed part of the Macquarie Park Innovation Summit Series 2021. A series of themed...

Minomic enters into collaboration with GloriousMed to introduce MiCheck^® Prostate into China

by Minomic | Apr 20, 2021

Sydney, April 20, 2021: GloriousMed Biomedical Group Co., Ltd (“GloriousMed”) and Minomic International Ltd (“Minomic”) of Australia officially executed the agreement, which formally launched the commercialization of MiCheck® Prostate, a...

CEO Dr Brad Walsh at the Pathology Technology Association Canberra Innovation Day 2021

by Minomic | Apr 6, 2021

On 24 March 2021 at Senate Alcove, Parliament House Canberra, Dr. Brad Walsh, CEO of Minomic International Ltd, opened the innovations panel discussion. He covered topics around the innovation environment in Australia and how the Government can assist in facilitating...

Minomic takes part in the NSW Going Global Export Program

by Minomic | Feb 11, 2021

At Minomic, we are proud to be part of the NSW Going Global Export Program, a NSW Government funded export assistance package, designed to boost NSW exports and unlock international markets for sustainable businesses following the impacts of COVID-19, the bushfires...

Industry News: MTPConnect’s COVID-19 Impact Report

by Minomic | Jun 17, 2020

Explore the impact of the pandemic lockdown on medtech, biotech and pharma sectors in Australia by downloading MTPConnect’s COVID-19 Impact...

Hot Off the Press – Minomic’s MiCheck^® Prospective Trial Papers Published

by Minomic | May 12, 2020

Minomic International Ltd (Minomic) is pleased to report publication of our back-to-back papers covering the recent MiCheck® prospective trial in the journal Urologic Oncology. The two papers, “A comparison of prostate health index, total PSA, %free PSA, and proPSA in...

« Older Entries

PUBLICATIONS

Development and evaluation of the MiCheck test for aggressive prostate cancer. Shore ND, Pieczonka CM, Henderson RJ, Bailen JL, Saltzstein DR, Concepcion RS, et al. Urol Oncol Semin Orig Investig. 2020.

A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population—The MiCheck-01 prospective trial Shore ND, Pieczonka CM, Henderson RJ, Bailen JL, Saltzstein DR, Concepcion RS, et al. Urol Oncol. 2020.

The Role of Glypican-1 in the Tumour Microenvironment. Lund ME, Campbell DH, Walsh BJ. Adv Exp Med Biol. 2020.

Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer. Campbell DH, Lund ME, Nocon AL, Cozzi PJ, Frydenberg M, De Souza P, et al. PLoS One. 2018.

Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker. Levin RA, Lund ME, Truong Q, Wu A, Shore ND, Saltzstein DR, et al. Oncotarget. 2018.

Glypican-1 as a biomarker for prostate cancer: Isolation and characterization. Truong Q, Justiniano IO, Nocon AL, Soon JT, Wissmueller S, Campbell DH, et al. J Cancer. 2016.

PATENTS

Minomic Patent Estate